上實發展(600748.SH):掛牌轉讓紹興上投100%股權及相應債權由立新印染、鑫億電子以3.65億元聯合競得
格隆匯12月8日丨上實發展(600748.SH)公佈,2021年11月19日,公司召開第八屆董事會第十二次(臨時)會議,審議通過公司全資子公司上投控股擬以人民幣3.2億元的起拍價通過產交所公開掛牌轉讓其所持有紹興上投100%股權及相應債權。
2021年12月8日,公司收到產交所關於上述掛牌轉讓事項的結果通知,最終由紹興市立新印染有限公司(“立新印染”)、紹興鑫億電子商務創業園有限公司(“鑫億電子”)聯合通過競價方式以人民幣3.65億元的價格成功摘牌。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.